ENTITY
WuXi XDC

WuXi XDC (2268 HK)

179
Analysis
Industrials • China
WuXi XDC is a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in antibody-drug conjugates (ADCs) and other bioconjugates. The company offers integrated, end-to-end services for the discovery, process development, and GMP manufacturing of bioconjugates, monoclonal antibody intermediates, and payload-linkers. WuXi XDC was founded in 2013 and is headquartered in Wuxi, China.
more
bearish•Eoflow
•12 Nov 2023 10:12

Weekly Deals Digest (12 Nov) - Eoflow, Benesse, Shidax, PS Mitsubishi, IRC, Hollysys, WuXi XDC

Last week, notable developments occurred in Event-Driven (Eoflow, Benesse, Shidax, PS Mitsubishi, CMIC, Cybernet, IRC, Hollysys, OreCorp, Tietto,...

Logo
680 Views
Share
•12 Nov 2023 08:08

ECM Weekly (12th Nov 2023)-Renesas, Bajaj, Alchip, Hybe, Will, Wuxi, ChaPanda, Chenqi, Cello, Honasa

Aequitas Research puts out a weekly update on the deals that were covered by the team recently along with updates for upcoming IPOs.

Logo
766 Views
Share
bullish•WuXi XDC
•09 Nov 2023 16:52

Wuxi XDC IPO: Forecasts and Valuation

​Wuxi plans to raise around US$479m through its HKEx IPO. We have valued the company's IPO using a DCF which offers more than 10% upside to the...

Share
bullish•WuXi XDC
•08 Nov 2023 10:05

WuXi XDC IPO: Valuation Insights

Blue-chip cornerstones will purchase US$300 million of the offer. Our base-case DCF valuation is HK$22.84 per share, 12.8% above the midpoint of...

Logo
728 Views
Share
bullish•WuXi XDC
•08 Nov 2023 02:15

WuXi XDC IPO Valuation Analysis: Premium Multiples Reflect 100%+ Top-Line Growth

WuXi XDC set terms for an upcoming IPO in Hong Kong. The company plans to raise ~$470M, and the IPO price range implies a market cap of ~$3B at the...

Share
x